Continuing Education Credits are not available for on demand offerings.
Broadcast time: 1 hour 45 minutes

Efforts by severely ill patients to gain access to experimental medicines continue to make headlines and raise fascinating ethical, policy, and legal questions.  At least 21 states have recently passed “Right to Try” laws that seek to make experimental drugs more readily available to severely ill patients.  Congress is also actively considering legislation.  This webinar will explore how recently-passed state “Right to Try” laws relate to the existing expanded access/compassionate use system.  An overview of these laws and the existing federal system will be provided.  The webinar will also examine the potential impact of pending federal “Right to Try” bills.  Specific issues to be addressed include patient eligibility, informed consent, impact on clinical trial enrollment, and corporate resources, liability issues, safety, and ethics.  Panelists will reflect the perspectives of industry, patients, clinical researchers, and regulators.